• 1. Enhanced corneal permeation of coumarin-6 using nanoliposomes containing dipotassium glycyrrhizinate: in vitro mechanism and in vivo permeation evaluation
  Chuanlong Guo,Fenghua Cui,Mengshuang Li,Fengjie Li,Xianggen Wu RSC Adv. 2015 5 75636
• 2. Surface modified nanoparticles and their applications for enantioselective detection, analysis, and separation of various chiral compounds
  Susanti,Asep Riswoko,Joddy Arya Laksmono,Galuh Widiyarti,Dadan Hermawan RSC Adv. 2023 13 18070
• 3. Visible light photocatalysis in the late-stage functionalization of pharmaceutically relevant compounds
  Rolando Cannalire,Sveva Pelliccia,Luca Sancineto,Ettore Novellino,Gian Cesare Tron,Mariateresa Giustiniano Chem. Soc. Rev. 2021 50 766
• 4. Kinetic modelling of acyl glucuronide and glucoside reactivity and development of structure–property relationships
  Peter R. Bradshaw,Selena E. Richards,Ian D. Wilson,Andrew V. Stachulski,John C. Lindon,Toby J. Athersuch Org. Biomol. Chem. 2020 18 1389
• 5. Insights into the mechanistic and synthetic aspects of the Mo/P-catalyzed oxidation of N-heterocycles
  Oleg V. Larionov,David Stephens,Adelphe M. Mfuh,Hadi D. Arman,Anastasia S. Naumova,Gabriel Chavez,Behije Skenderi Org. Biomol. Chem. 2014 12 3026

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrans Chromenopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrans 1-benzopyrans Chromenopyridines

Pranoprofen and Its Significance in Modern Pharmaceutical Research

Pranoprofen, a compound with the CAS number 52549-17-4, has emerged as a noteworthy entity in the realm of pharmaceutical chemistry. This compound, characterized by its unique molecular structure and pharmacological properties, has garnered significant attention from researchers and pharmaceutical companies worldwide. The exploration of Pranoprofen's mechanisms of action, therapeutic applications, and potential for drug development represents a critical area of study in contemporary medicinal chemistry.

The chemical structure of Pranoprofen, denoted by its CAS number 52549-17-4, is a testament to the intricate design inherent in modern drug discovery. This compound belongs to the class of propionic acid derivatives, which are known for their diverse pharmacological activities. The specific arrangement of functional groups in Pranoprofen contributes to its unique interaction with biological targets, making it a promising candidate for further investigation.

In recent years, the pharmaceutical industry has witnessed a surge in interest towards non-steroidal anti-inflammatory drugs (NSAIDs). Pranoprofen, with its potent anti-inflammatory and analgesic properties, has positioned itself as a potential contender in this domain. Current research indicates that Pranoprofen exhibits a higher selectivity for cyclooxygenase-2 (COX-2) over cyclooxygenase-1 (COX-1), which is a significant advantage in minimizing gastrointestinal side effects associated with traditional NSAIDs.

The synthesis and characterization of Pranoprofen have been subjects of extensive study. Advanced synthetic methodologies have enabled researchers to produce Pranoprofen with high purity and yield, facilitating its use in both preclinical and clinical trials. The structural elucidation of Pranoprofen using techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry has provided valuable insights into its molecular interactions and pharmacophore identification.

One of the most compelling aspects of Pranoprofen is its potential application in treating chronic inflammatory conditions. Studies have demonstrated that Pranoprofen can modulate inflammatory pathways by inhibiting key enzymes involved in the production of prostaglandins. This mechanism not only alleviates pain and inflammation but also holds promise for the management of conditions such as rheumatoid arthritis and osteoarthritis.

The pharmacokinetic profile of Pranoprofen is another area that has attracted considerable attention. Research suggests that Pranoprofen exhibits good oral bioavailability and a favorable half-life, which allows for once-daily dosing. This attribute is particularly advantageous for patient compliance and convenience. Additionally, studies have shown that Pranoprofen undergoes minimal metabolism by cytochrome P450 enzymes, reducing the risk of drug-drug interactions.

Recent advancements in computational chemistry have further enhanced our understanding of Pranoprofen's pharmacological properties. Molecular docking studies have identified key binding sites on target proteins, providing insights into the compound's mechanism of action. These findings have guided the design of novel analogs with improved efficacy and reduced side effects.

The clinical development of Pranoprofen has been progressing steadily. Several Phase II clinical trials have reported promising results regarding its efficacy in pain relief and anti-inflammatory effects. These trials have also highlighted the safety profile of Pranoprofen, with minimal adverse effects observed at therapeutic doses. The upcoming Phase III trials are expected to provide more comprehensive data on its long-term efficacy and safety.

The role of Pranoprofen in personalized medicine is an emerging area of research. Genetic variations among individuals can influence their response to drugs, including Pranoprofen. By integrating genetic data with pharmacological insights, researchers aim to develop tailored treatment strategies that maximize therapeutic benefits while minimizing adverse effects.

In conclusion, Pranoprofen stands as a significant compound in the field of pharmaceutical chemistry. Its unique molecular structure, potent pharmacological effects, and favorable pharmacokinetic profile make it a promising candidate for treating various inflammatory conditions. Ongoing research continues to unravel new aspects of its mechanism of action and therapeutic applications, paving the way for innovative drug development strategies.

• 52549-19-6(a-Methyl-5-oxo-5H-1benzopyrano2,3-bpyridine-7-acetic Acid)
• 53944-31-3(7-Ethyl-5-oxo-5H-1benzopyrano2,3-bpyridine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)